Research ExplorerPublicationsImpact of prior JAK-inhibitor therapy with ruxolitinib on ou...

Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT

Standard

Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT. / Kröger, Nicolaus; Sbianchi, Giulia; Sirait, Tiarlan; Wolschke, Christine; Beelen, Dietrich; Passweg, Jakob; Robin, Marie; Vrhovac, Radovan; Helbig, Grzegorz; Sockel, Katja; Conneally, Eibhlin; Rubio, Marie Thérèse; Beguin, Yves; Finke, Jürgen; Bernasconi, Paolo; Morozova, Elena; Clausen, Johannes; von dem Borne, Peter; Schaap, Nicolaas; Schroyens, Wilfried; Patriarca, Francesca; Di Renzo, Nicola; Yeğin, Zeynep Arzu; Hayden, Patrick; McLornan, Donal; Yakoub-Agha, Ibrahim.

In: LEUKEMIA, Vol. 35, No. 12, 12.2021, p. 3551-3560.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Kröger, N, Sbianchi, G, Sirait, T, Wolschke, C, Beelen, D, Passweg, J, Robin, M, Vrhovac, R, Helbig, G, Sockel, K, Conneally, E, Rubio, MT, Beguin, Y, Finke, J, Bernasconi, P, Morozova, E, Clausen, J, von dem Borne, P, Schaap, N, Schroyens, W, Patriarca, F, Di Renzo, N, Yeğin, ZA, Hayden, P, McLornan, D & Yakoub-Agha, I 2021, 'Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT', LEUKEMIA, vol. 35, no. 12, pp. 3551-3560. https://doi.org/10.1038/s41375-021-01276-4

APA

Kröger, N., Sbianchi, G., Sirait, T., Wolschke, C., Beelen, D., Passweg, J., Robin, M., Vrhovac, R., Helbig, G., Sockel, K., Conneally, E., Rubio, M. T., Beguin, Y., Finke, J., Bernasconi, P., Morozova, E., Clausen, J., von dem Borne, P., Schaap, N., ... Yakoub-Agha, I. (2021). Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT. LEUKEMIA, 35(12), 3551-3560. https://doi.org/10.1038/s41375-021-01276-4

Vancouver

Kröger N, Sbianchi G, Sirait T, Wolschke C, Beelen D, Passweg J et al. Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT. LEUKEMIA. 2021 Dec;35(12):3551-3560. https://doi.org/10.1038/s41375-021-01276-4

Bibtex

@article{02b485ea96124465acc27b169fa064ab,
title = "Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT",
abstract = "JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) remains to be determined. We evaluated the impact of RUX on outcome in 551 myelofibrosis patients who received HSCT without (n = 274) or with (n = 277) RUX pretreatment. The overall leukocyte engraftment on day 45 was 92% and significantly higher in RUX responsive patients than those who had no or lost response to RUX (94% vs. 85%, p = 0.05). The 1-year non-relapse mortality was 22% without significant difference between the arms. In a multivariate analysis (MVA) RUX pretreated patients with ongoing spleen response at transplant had a significantly lower risk of relapse (8.1% vs. 19.1%; p = 0.04)] and better 2-year event-free survival (68.9% vs. 53.7%; p = 0.02) in comparison to patients without RUX pretreatment. For overall survival the only significant factors were age > 58 years (p = 0.03) and HLA mismatch donor (p = 0.001). RUX prior to HSCT did not negatively impact outcome after transplantation and patients with ongoing spleen response at time of transplantation had best outcome.",
author = "Nicolaus Kr{\"o}ger and Giulia Sbianchi and Tiarlan Sirait and Christine Wolschke and Dietrich Beelen and Jakob Passweg and Marie Robin and Radovan Vrhovac and Grzegorz Helbig and Katja Sockel and Eibhlin Conneally and Rubio, {Marie Th{\'e}r{\`e}se} and Yves Beguin and J{\"u}rgen Finke and Paolo Bernasconi and Elena Morozova and Johannes Clausen and {von dem Borne}, Peter and Nicolaas Schaap and Wilfried Schroyens and Francesca Patriarca and {Di Renzo}, Nicola and Yeğin, {Zeynep Arzu} and Patrick Hayden and Donal McLornan and Ibrahim Yakoub-Agha",
year = "2021",
month = dec,
doi = "10.1038/s41375-021-01276-4",
language = "English",
volume = "35",
pages = "3551--3560",
journal = "LEUKEMIA",
issn = "0887-6924",
publisher = "NATURE PUBLISHING GROUP",
number = "12",

}

RIS

TY - JOUR

T1 - Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT

AU - Kröger, Nicolaus

AU - Sbianchi, Giulia

AU - Sirait, Tiarlan

AU - Wolschke, Christine

AU - Beelen, Dietrich

AU - Passweg, Jakob

AU - Robin, Marie

AU - Vrhovac, Radovan

AU - Helbig, Grzegorz

AU - Sockel, Katja

AU - Conneally, Eibhlin

AU - Rubio, Marie Thérèse

AU - Beguin, Yves

AU - Finke, Jürgen

AU - Bernasconi, Paolo

AU - Morozova, Elena

AU - Clausen, Johannes

AU - von dem Borne, Peter

AU - Schaap, Nicolaas

AU - Schroyens, Wilfried

AU - Patriarca, Francesca

AU - Di Renzo, Nicola

AU - Yeğin, Zeynep Arzu

AU - Hayden, Patrick

AU - McLornan, Donal

AU - Yakoub-Agha, Ibrahim

PY - 2021/12

Y1 - 2021/12

N2 - JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) remains to be determined. We evaluated the impact of RUX on outcome in 551 myelofibrosis patients who received HSCT without (n = 274) or with (n = 277) RUX pretreatment. The overall leukocyte engraftment on day 45 was 92% and significantly higher in RUX responsive patients than those who had no or lost response to RUX (94% vs. 85%, p = 0.05). The 1-year non-relapse mortality was 22% without significant difference between the arms. In a multivariate analysis (MVA) RUX pretreated patients with ongoing spleen response at transplant had a significantly lower risk of relapse (8.1% vs. 19.1%; p = 0.04)] and better 2-year event-free survival (68.9% vs. 53.7%; p = 0.02) in comparison to patients without RUX pretreatment. For overall survival the only significant factors were age > 58 years (p = 0.03) and HLA mismatch donor (p = 0.001). RUX prior to HSCT did not negatively impact outcome after transplantation and patients with ongoing spleen response at time of transplantation had best outcome.

AB - JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) remains to be determined. We evaluated the impact of RUX on outcome in 551 myelofibrosis patients who received HSCT without (n = 274) or with (n = 277) RUX pretreatment. The overall leukocyte engraftment on day 45 was 92% and significantly higher in RUX responsive patients than those who had no or lost response to RUX (94% vs. 85%, p = 0.05). The 1-year non-relapse mortality was 22% without significant difference between the arms. In a multivariate analysis (MVA) RUX pretreated patients with ongoing spleen response at transplant had a significantly lower risk of relapse (8.1% vs. 19.1%; p = 0.04)] and better 2-year event-free survival (68.9% vs. 53.7%; p = 0.02) in comparison to patients without RUX pretreatment. For overall survival the only significant factors were age > 58 years (p = 0.03) and HLA mismatch donor (p = 0.001). RUX prior to HSCT did not negatively impact outcome after transplantation and patients with ongoing spleen response at time of transplantation had best outcome.

U2 - 10.1038/s41375-021-01276-4

DO - 10.1038/s41375-021-01276-4

M3 - SCORING: Journal article

C2 - 34023851

VL - 35

SP - 3551

EP - 3560

JO - LEUKEMIA

JF - LEUKEMIA

SN - 0887-6924

IS - 12

ER -